Taking people in GermanyPhase 1/2
Long-term follow-up of people treated with Miltenyi CAR T cell therapies
Follows people with blood cancers treated with modified immune cells over time.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Key facts
- Where
- Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, and Wuerzburg, GermanySee the 9 sites
- Phase
- Phase 1/2
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- University Hospital Cologne AöRCologne, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
- Universitaetsklinikum Muenster AöRMuenster, GermanyTaking people
- Westfaelische Wilhelms-Universitaet MuensterMuenster, GermanyTaking people
- Klinikum der Universitaet Muenchen AöRMunich, GermanyTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Miltenyi Biomedicine GmbH
- Trial code
- NCT06508775EU 2022-501648-14-00
- Record updated
- 9 October 2026
- Original description
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.Read full original descriptionShow less
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
Inclusion: Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up; Patient has provided informed consent prior to enrollment.
Exclusion: No exclusion criteria.